RxDoctor Payments Data

Ibrahim Majzoub, MD

Pulmonary Disease · Chicago, ILNPI 1366537409

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Baxter Healthcare at 27.0% of the total. Reporting peaked in 2024 at $278 and has fallen 87.9% since, to $34 in 2025. That places this record below the midpoint for pulmonary disease clinicians in IL, where the typical reported total is $1,325.

$926in general payments, 2019–2025

Across 13 payments — averaging $71.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$250
  • Medtronic$144
  • Jazz Pharmaceuticals Inc.$127
  • Amgen$103
  • Sun Pharmaceutical Industries Inc.$100
  • Intuitive Surgical$97
  • plus $105 from 3 others

What the payments were for

  • Food & beverage$926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$926 in reported general payments places this provider in the 45th percentile of 539 pulmonary disease providers in Illinois.

See all pulmonary disease providers in Illinois →

Medicare billing

Part B allowed, 2024
$262,554
Medicare patients
215
Services billed
1,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$8,894
Enoxaparin Sodium15$1,289
Atorvastatin Calcium23$432
Famotidine19$344
Albuterol Sulfate HfaAlbuterol Sulfate13$261
Pantoprazole Sodium13$240
Quetiapine Fumarate14$233
MethotrexateMethotrexate Sodium22$231
Metoprolol Tartrate16$147
Spironolactone12$114
Furosemide13$81

Paid to pharmacies, not to this prescriber.

Other pulmonary disease in Chicago

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →